uniQure (QURE) Current Assets (2015 - 2026)
uniQure (QURE) posted quarterly Current Assets of $834.3 million for Q2 2026, up 104.19% year-over-year from $408.6 million in Q2 2025, and up 35.49% quarter-over-quarter from $615.7 million in Q1 2026.
Analysis
uniQure (QURE) Current Assets (2015 - 2026) Analysis & Trends
uniQure's Current Assets history runs 12 years deep, the most recent figure standing at $834.3 million for Q2 2026.
- In Q2 2026, Current Assets rose 104.19% year-over-year to $834.3 million; the TTM figure through Jun 2026 stood at $834.3 million (up 104.19% YoY), while the FY2025 annual figure was $656.0 million, up 68.08% from the prior year.
- Current Assets for Q2 2026 stood at $834.3 million, up from $615.7 million in the prior quarter.
- The five-year high for Current Assets was $834.3 million in Q2 2026, with the low at $390.3 million in Q4 2024.
- The 5-year median for Current Assets is $585.1 million (2022), against an average of $572.0 million.
- The sharpest annual moves came in 2022 and 2024: Current Assets soared 104.8% in 2022, then plunged 40.13% in 2024.
- uniQure's Current Assets stood at $476.8 million in 2022, then jumped by 36.72% to $651.9 million in 2023, then tumbled by 40.13% to $390.3 million in 2024, then jumped by 68.08% to $656.0 million in 2025, then climbed by 27.18% to $834.3 million in 2026.
- Business Quant data shows QURE's Current Assets at $834.3 million in Q2 2026, $615.7 million in Q1 2026, and $656.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 834.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 834.27 Mn |
| Mar 31, 2026 | 615.74 Mn |
| Dec 31, 2025 | 655.99 Mn |
| Sep 30, 2025 | 716.19 Mn |
| Jun 30, 2025 | 408.57 Mn |
| Mar 31, 2025 | 435.42 Mn |
| Dec 31, 2024 | 390.29 Mn |
| Sep 30, 2024 | 464.14 Mn |
| Jun 30, 2024 | 591.97 Mn |
| Mar 31, 2024 | 596.00 Mn |
| Dec 31, 2023 | 651.85 Mn |
| Sep 30, 2023 | 693.63 Mn |
| Jun 30, 2023 | 756.96 Mn |
| Mar 31, 2023 | 442.64 Mn |
| Dec 31, 2022 | 476.77 Mn |
| Sep 30, 2022 | 464.58 Mn |
| Jun 30, 2022 | 523.30 Mn |
| Mar 31, 2022 | 578.21 Mn |
| Dec 31, 2021 | 628.24 Mn |
| Sep 30, 2021 | 593.76 Mn |